SCHEMBL4672168

SCHEMBL4672168

Clc1cc(-c2ccncc2)ccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
MAPT P10636 1/20 0.52
IDO1 P14902 1/20 0.48
SMARCA2 P51531 1/20 0.47
SMARCA4 P51532 1/20 0.47
CCNC P24863 1/20 0.46
CDK8 P49336 1/20 0.46
QDPR P09417 1/20 0.45
NOTUM Q6P988 1/20 0.44
AAK1 Q2M2I8 1/20 0.44
RECQL P46063 1/20 0.43
LOX P28300 1/20 0.43
LOXL3 P58215 1/20 0.43
LOXL2 Q9Y4K0 1/20 0.43
PDGFRB P09619 1/20 0.43
PDGFRA P16234 1/20 0.43
CYP19A1 P11511 1/20 0.42
DYRK1A Q13627 1/20 0.42
S1PR1 P21453 1/20 0.41
S1PR3 Q99500 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4027001 0.90 IDO1 (0.55) IDO1CCNCCDK8RECQLLOX
SCHEMBL3500189 0.84 MAP4K4 (0.49) MAPTIDO1CCNCCDK8RECQL
SCHEMBL29461217 0.84 ADORA2A (0.56) IDO1CCNCCDK8NOTUMRECQL
SCHEMBL2329610 0.84 ADORA2A (0.56) IDO1CCNCCDK8NOTUMRECQL
SCHEMBL25070215 0.82 ADORA2A (0.54) IDO1CCNCCDK8NOTUMCYP19A1
SCHEMBL4753951 0.80 IDO1 (0.49) IDO1SMARCA2SMARCA4CCNCCDK8
SCHEMBL27722982 0.80 IDO1 (0.44) IDO1CCNCCDK8RECQLLOX
SCHEMBL28163101 0.80 CCNC (0.46) MAPTIDO1CCNCCDK8AAK1
SCHEMBL12050763 0.80 ESR2 (0.47) MAPTIDO1CCNCCDK8RECQL
SCHEMBL4932513 0.80 MAPK14 (0.52) MAPTIDO1CCNCCDK8RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116726994-B Preparation method and application of Salen (M) porous ionic polymer heterogeneous catalyst 昆明理工大学 2024-11-22 CN claimed
CN-116726994-A Preparation method and application of Salen (M) porous ionic polymer heterogeneous catalyst 昆明理工大学 2023-09-12 CN claimed
CN-116239517-A All-organic perovskite material and preparation method thereof 南方科技大学 2023-06-09 CN claimed
CN-111925321-B Paraquat hapten, complete antigen, antibody, detection test paper and kit 北京纳百生物科技有限公司 2020-12-29 CN claimed
CN-111925321-A Paraquat hapten, complete antigen, antibody, detection test paper and kit 北京纳百生物科技有限公司 2020-11-13 CN claimed
CN-116726994-B Preparation method and application of Salen (M) porous ionic polymer heterogeneous catalyst 昆明理工大学 2024-11-22 CN disclosed
CN-114904356-B Method for separating nitrogen and oxygen 中国科学院大连化学物理研究所 2024-03-26 CN disclosed
CN-116726994-A Preparation method and application of Salen (M) porous ionic polymer heterogeneous catalyst 昆明理工大学 2023-09-12 CN disclosed
US-20230271960-A1 AMINO ACID COMPOUNDS AND METHODS OF USE PLIANT THERAPEUTICS INC (US) 2023-08-31 US disclosed
US-20230181546-A1 TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS PLIANT THERAPEUTICS INC (US) 2023-06-15 US disclosed
CN-116239517-A All-organic perovskite material and preparation method thereof 南方科技大学 2023-06-09 CN disclosed
CN-114904356-A Method for separating nitrogen and oxygen 中国科学院大连化学物理研究所 2022-08-16 CN disclosed
EP-1503757-A4 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2005-11-16 EP disclosed
US-20050176753-A1 controlling signal transduction; anticancer agents; antitumor agnets; atherosclerosis; vision defects; antidiabetic agents; antiinflammatory agents MERCK SHARP & DOHME CORP. 2005-08-11 US disclosed
EP-1503757-A2 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2005-02-09 EP disclosed
WO-2003092595-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC (US) 2003-11-13 WO disclosed
US-6174901-B1 FOR TREATMENT OF RHEUMATOID ARTHRITIS, PAGETS DISEASE, OSTEOPHOROSIS, MULTIPLE MYELOMA, UVEITITIS, ACUTE OR CHRONIC MYELOGENOUS LEUKEMIA, PANCREATIC .BETA. CELL DESTRUCTION, OSTEOARTHRITIS, RHEUMATOID SPONDYLITIS, GOUTY ARTHRITIS ETC. AMGEN INC. 2001-01-16 US disclosed
EP-1042293-A1 SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE Amgen Inc. (US) 2000-10-11 EP disclosed
WO-1999032448-A1 SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE AMGEN INC. (US) 1999-07-01 WO disclosed
US-4550166-A SEDATIVES, TRANQUILIZERS, TENSION REDUCERS AMERICAN CYANAMID COMPANY (US) 1985-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271960-A1 AMINO ACID COMPOUNDS AND METHODS OF USE ITGB6, ITGA6, ITGA5 LMNA 3365/4885MAPT 3892/4885IDO1 2131/4885
US-20050176753-A1 controlling signal transduction; anticancer agents; antitumor agnets; atherosclerosis; vision defects; antidiabetic agents; antiinflammatory agents IRAK4, MAP3K4, MAP3K1 LMNA 4430/4885MAPT 1620/4885IDO1 767/4885
US-20230181546-A1 TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS ITGA5, ITGAL, ITGB5 LMNA 3362/4885MAPT 4071/4885IDO1 4293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.